TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Relative abundance of microbiome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alpha diversity of microbiome (Shannon diversity index)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alpha diversity of microbiome (Fisher's index)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alpha diversity of microbiome (Faith's phylogenetic diversity whole tree)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recall testing
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Overall Complete Response (OCR) Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Arch dimension
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in sleep quality measured as duration of sleep stages
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Effective immune response (EIR) rate at 28 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: area under the concentration-time curve from time of dosing extrapolated to time infinity (AUCinf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immune response to PA2024
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Post-exercise muscle protein synthesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Endurance of deep neck flexor muscle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Time in range (TIR) between 140 and 180 mg/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Collateral Circulation grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: cumulative doses of PCA butorphanol consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients with cystoscopic CR at 48 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nature, incidence, relatedness, and severity of all AEs and SAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Patients successfully weaned from VV-ECMO
Endpoint domain: Mortality/survival
Primary endpoint: Safety of L19TNF plus lomustine
Endpoint domain: Adverse events/effects
Primary endpoint: Number of subjects with negative oral food challenge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: United Parkinson's disease Rating Scale part 3: Motor Examination Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Dementia Rating Scale Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Changes in White blood cells (WBC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Changes in resting systolic (SBP) and diastolic blood pressure (DBP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Improvement of Post-COVID symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of physical and/or mental fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Change of cognitive impairment
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Disruptive behavior change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Autism symptoms change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients with >= grade 2 hearing loss
Endpoint domain: Adverse events/effects
Primary endpoint: Diet quality in preconception
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of VT Carriage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percentage of Participants with Responder Status of Extremely Satisfied or Satisfied
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Heart color ultrasound evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Occurrence of shigellosis
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Incident Pancreatic Cancers or High-Grade Pancreatic Neoplasms
Endpoint domain: Mortality/survival
Primary endpoint: Number of Imaging-Positive Pancreatic Cancers or High-Grade Neoplasms
Endpoint domain: Mortality/survival
Primary endpoint: Number of Imaging-Negative, Assay-Positive Pancreatic Cancers or High-Grade Neoplasms
Endpoint domain: Mortality/survival
Primary endpoint: Change from Baseline Geometric mean titer (GMT) ratio of antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in accumulation of amyloid plaque (18F-Florbetapir PET)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in Alzheimer's Disease Cooperative Study-Preclinical Alzheimer Cognitive Composite (PAAC) cognitive composite score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Alzheimer's Disease Cooperative Study-Activities of Daily Living scale-PI (ADCS-ADL-PI) score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Patient Reported Outcome Scores: Fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Number of Participants with One or More Adverse Event(s) and Serious Adverse Event(s)
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum tolerated dose (MTD) of olaparib with magrolimab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Worsening HF Events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Muscle Weakness Torque
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Accuracy of elbow ultrasonography for diagnosing elbow fractures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Compliance with compress application
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Occurrence of adverse events from compress application
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement in patient reported outcome measures
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of participants who reported serious adverse event (SAE)/drug reaction (SADR)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of participants who reported unexpected adverse event (AE)/drug reaction (ADR)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of participants who reported known (labeled) ADR
Endpoint domain: Adverse events/effects
Primary endpoint: Modified Yale Preoperative Anxiety Scale (mYPAS) scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Biomechanical plantar pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biomechanical Propulsion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cord blood alarin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gap reduction in mouth opening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment-related adverse event (tAE) rate
Endpoint domain: Adverse events/effects
Primary endpoint: Calorie nutritional goals
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Days free from mechanical ventilation and/or vasopressors and/or renal replacement therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve from time zero to time of the last quantifiable concentration[AUC(0-T)]
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve from time zero extrapolated to infinite time[AUC(INF)]
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of time in hypoglycemic range <3.9 mmol/L (<70 mg/dL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of time in hyperglycemic range >13.9 mmol/L (>250 mg/dL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 30 m sprint performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma terpinolene concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in salivary cortisol (alcohol)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in salivary cortisol (stress induction)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in Alcohol Demand (stress induction)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Alcohol Demand (alcohol)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Alcohol Urge (stress)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Alcohol Urge (alcohol)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall bone fusion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Overall fusion success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Occurrence of AVF complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Validation of the MaiRa Preeclampsia Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Striatal uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Infant Body Mass Index Z-score (BMIZ) at 13 and 24 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Infant dietary quality index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Infant self-regulation during feeding
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Eating self-regulation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Prevalence of Intestinal Parasitic Infections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percent of samples adequate for sequencing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Berg balance Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of participants experiencing episodes of severe hypoglycaemia
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of participants experiencing episodes of diabetic ketoacidosis
Endpoint domain: Adverse events/effects
Primary endpoint: Complete resolution of UTI symptoms at Day 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in UTISA symptom severity scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immune-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in QRISK3 score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Diagnostic accuracy of ROX
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to invasive mechanical ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Assessment of Adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Percent positive and negative agreement of the Multiplo® TP/HIV Self-Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Warm ischemia time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Completion of post-partum 6-week comprehensive visit
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in Frontal Alpha Power
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of participants with postoperative atrial fibrillation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Immune Status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Screen-detected breast cancers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Hazard rate of Revision due to any cause
Endpoint domain: Mortality/survival
Primary endpoint: Hazard rate of Revision due to infection
Endpoint domain: Adverse events/effects
Primary endpoint: Pain Intensity as Assessed by Visual Analog Scale (VAS) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain Intensity as Assessed by Verbal Pain Score (VPS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Competitive Employment
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Change in Job Interview Skills
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Employment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in size of intracranial bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hemoglobin A1C Progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Patient and Provider/Clinic Staff Satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Knowledge assessment (test score)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in pulmonary fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Modified Tardieu Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Evaluation of Proprioceptive Awareness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Evaluation of static and dynamic balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Cocaine-negative UDS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of congenital heart diseases
Endpoint domain: Mortality/survival
Primary endpoint: Prevalence of congenital heart diseases
Endpoint domain: Mortality/survival
Primary endpoint: Pediatric anesthesia satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: time of remission of neurostorm symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: changes in Glasgow Coma Scale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Psychological well-being (child)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Proportion healed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Computerized Adaptive Testing Scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Femoral artery diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Femoral artery shear rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Femoral artery Blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Total Diabetes Distress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Compliance with dietary intervention
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in Hospital Anxiety and Depression Score (HADS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Patient Health Questionnaire PHQ-9 Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Pittsburgh Sleep Quality Index (PSQI) Score
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Change in Mindful Attention Awareness Scale (MAAS)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Eating Disorder Examination (EDE) global score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in treatments for overweight/obesity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in comorbidities of overweight/obesity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of Difamilast ointment in treating mild to moderate AD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in FEV1 compared to baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Knee extension angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Targeted Nail Psoriasis Severity Index (tNAPSI) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Ventriculo-peritoneal shunt (VPS) dependency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: correspondence between brain tumor cells and ROI signal intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: visibility of white matter tracts on 7T MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Geometric Mean Titer (GMT) of Serum RSV-A Neutralizing Antibodies (Abs) at Day 29
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Respiratory Rate Oxygenation (ROX) Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Thyroid-Related Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Proportion of type of first-line treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of Participants With Clinical Symptom Improvement at Day 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Treatment Success at Day 7
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Serious Adverse Events and Non-Serious Adverse Events With Explicit Attribution to Ceftazidime-Avibactam
Endpoint domain: Adverse events/effects
Primary endpoint: Conners Rating Scale
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Morphologic complete remission (CR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients who develop drug-related non-hematologic grade 3 or higher toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Number of patients who develop drug-related non-hematologic grade 3 or higher toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Success rate of scalp cooling in preventing chemotherapy-induced alopecia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Functional exercises capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Upper extremity normal range of motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: prevalence and degree of glottic or supraglottic collapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time of onset of the laryngeal obstruction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Observed duration of the laryngeal obstruction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Work and Social Adjustment Scale (WSAS)
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Willingness to participate in a future full Fasting Mimicking Diet (FMD) clinical trial
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in analgesia use
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Safety and tolerability of BPI-421286
Endpoint domain: Adverse events/effects
Primary endpoint: Successful adjustment procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Activity engagement change
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Symptom distress change
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Grade 3+ SBRT-related toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Percent Change In Lactate Dehydrogenase (LDH) Levels Normalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Employee Satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Variation of signal intensity of deuterated exhaled metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Vascular Dementia Cognitive Assessment Scale (VADAS-cog)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Distance walked during the 6MWT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perioperative Complication Rate
Endpoint domain: Adverse events/effects